RNA m
Epigenetic modification
Immunotherapy
N6-methyladenosine
Prostate cancer
RNA modification
Journal
Biochimica et biophysica acta. Reviews on cancer
ISSN: 1879-2561
Titre abrégé: Biochim Biophys Acta Rev Cancer
Pays: Netherlands
ID NLM: 9806362
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
received:
04
05
2023
revised:
21
06
2023
accepted:
23
07
2023
medline:
7
9
2023
pubmed:
29
7
2023
entrez:
28
7
2023
Statut:
ppublish
Résumé
Prostate cancer (PCa) is the most common malignant tumor and the second leading cause of cancer-related mortality in men worldwide. Despite significant advances in PCa therapy, the underlying molecular mechanisms have yet to be fully elucidated. Recently, epigenetic modification has emerged as a key player in tumor progression, and RNA-based N6-methyladenosine (m
Identifiants
pubmed: 37507057
pii: S0304-419X(23)00110-5
doi: 10.1016/j.bbcan.2023.188961
pii:
doi:
Substances chimiques
Adenosine
K72T3FS567
RNA
63231-63-0
Types de publication
Systematic Review
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
188961Informations de copyright
Copyright © 2023 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.